CQC-regulated clinics & online consultations
Posted on October 29, 2026 by Sally-Anne Turner
You’ve struggled with binge eating for years. Those episodes where you eat rapidly, feel out of control, and consume large amounts of food even when you’re not hungry. The shame afterwards. The promises to yourself that it won’t happen again. And then it does.
Now you’ve heard about weight loss injections like Wegovy or Mounjaro, and you’re wondering: could these medications help? Could they reduce the urges that have felt so difficult to manage?
These questions are important, and they deserve careful, evidence-based answers. The relationship between GLP-1 weight loss medications and binge eating disorder is complex and still being investigated. Early research suggests possible effects on binge eating behaviours, but the evidence remains limited.
Importantly, Wegovy and Mounjaro are not licensed in the UK to treat binge eating disorder. For someone with an eating disorder, appetite suppression and weight loss can also create additional concerns.
This guide explores the evidence, potential benefits, risks and what appropriate treatment might involve when you’re managing both weight concerns and binge eating patterns. For broader context on mental health considerations with weight loss medications, see our comprehensive guide on Weight Loss Injections and Mental Health: A Balanced Guide.
Before exploring how weight loss medications might affect binge eating, it’s worth clarifying what binge eating disorder actually is.
Many people occasionally overeat, particularly at celebrations or during stressful periods. Binge eating disorder is different.
A binge eating episode typically involves consuming an unusually large amount of food within a defined period, accompanied by a sense of loss of control.
You may feel unable to stop eating or control how much you’re consuming.
Under commonly used diagnostic criteria, episodes occur at least once a week for three months, alongside significant distress and other characteristic symptoms.
These may include eating more rapidly than usual, eating until uncomfortably full, eating when not physically hungry, eating alone because of embarrassment, or experiencing guilt or distress afterwards.
Unlike bulimia nervosa, binge eating disorder does not involve recurrent inappropriate compensatory behaviours such as self-induced vomiting or misuse of laxatives.
However, people may experience different eating disorder symptoms over time, making individual assessment important.
Binge eating disorder is not simply about hunger or enjoying food.
Psychological and emotional factors can contribute, including stress, anxiety, low mood and difficulties managing distress.
Some people describe using food to cope with uncomfortable emotions, while others experience binge episodes in response to restrictive eating patterns or other triggers.
The causes are complex and vary between individuals.
Some people have experienced trauma, while others have not. Trauma should not automatically be assumed to be the underlying cause of binge eating disorder.
Understanding the factors contributing to someone’s symptoms is an important part of psychological treatment.
Binge eating disorder can occur at any body weight.
Some people experience weight gain, while others do not. Body weight alone cannot determine whether someone has an eating disorder or how severe it is.
Repeated attempts at restrictive dieting may also contribute to cycles of hunger, binge eating and distress.
Weight stigma and negative experiences relating to body image can create additional psychological challenges.
Importantly, treatment for binge eating disorder should focus on reducing binge eating behaviours and improving psychological wellbeing rather than making weight loss the immediate goal.
GLP-1-based medicines such as Wegovy (semaglutide) and Mounjaro (tirzepatide) are licensed for specific medical indications, including weight management in eligible patients.
They are not licensed in the UK as treatments for binge eating disorder.
However, researchers are investigating whether their effects on appetite and food-related behaviours could have implications for people experiencing binge eating.
Wegovy acts on GLP-1 receptors involved in appetite regulation and glucose control.
Mounjaro activates both GLP-1 and GIP receptors.
These medicines can reduce hunger, increase feelings of fullness and delay gastric emptying.
Researchers are also investigating how GLP-1-related pathways may influence food cravings and reward processing.
For someone experiencing binge eating, these effects might influence the urge to eat, or the amount of food consumed.
However, binge eating disorder involves more than appetite alone.
Reducing hunger does not necessarily address loss of control, emotional distress, restrictive eating patterns or other psychological factors associated with the condition.
Some people with binge eating disorder experience a cycle involving emotional distress, binge eating and feelings of guilt or shame.
If medication reduces appetite or food-related preoccupation, it may change aspects of this experience.
However, it would be premature to conclude that GLP-1 medicines reliably interrupt binge eating cycles or provide an established treatment benefit.
There is also a potential concern that strong appetite suppression could encourage restrictive eating in vulnerable individuals.
This is important because restriction may worsen binge eating patterns.
Psychological treatment remains central to managing the condition.
Research into GLP-1 medicines and binge eating disorder is still at an early stage.
Small studies have investigated medicines including liraglutide and semaglutide, with some reporting improvements in measures of binge eating.
However, findings have been inconsistent, and the available studies have important limitations.
For example, a small, randomised trial of liraglutide in people with binge eating disorder did not establish a statistically significant advantage over placebo for its primary binge eating outcome, although weight loss differed between groups.
It would therefore be misleading to claim that liraglutide has been proven to reduce binge eating days by 50% compared with placebo.
Research involving semaglutide and other newer treatments is also developing, but larger, well-designed clinical trials are needed.
Weight-loss results from major Wegovy or Mounjaro trials should not be used as evidence that these medicines treat binge eating disorder.
The MHRA’s guidance on GLP-1 medicines explains their licensed uses and important safety considerations.
Having binge eating disorder does not automatically answer whether someone is suitable for GLP-1-based weight management.
The decision requires individual assessment, particularly because treatment for an eating disorder and treatment for obesity may have different immediate goals.
If you have binge eating disorder alongside obesity or another weight-related health concern, your healthcare team may need to consider both conditions.
However, a diagnosis of binge eating disorder does not itself establish eligibility for GLP-1 medication.
Your clinician must consider the medicine’s licensed indication, your medical history and whether appetite suppression could interfere with eating disorder treatment.
Where weight management is clinically appropriate, the timing and approach should be coordinated with eating disorder care.
It is important not to assume that treating body weight will automatically resolve binge eating symptoms.
NICE recommends a binge-eating-disorder-focused guided self-help programme as the first treatment option for adults.
If guided self-help is unsuitable or ineffective, eating-disorder-focused cognitive behavioural therapy (CBT-ED) should be offered.
Medication should not be offered as the sole treatment for binge eating disorder.
If you’ve tried psychological treatment and continue to experience symptoms, this does not automatically mean GLP-1 medication is the next recommended treatment.
Your eating disorder team can review your diagnosis, treatment response and other appropriate options.
If you also meet the criteria for medical weight management, that can be considered separately as part of a coordinated care plan.
Some people with binge eating disorder also have conditions such as type 2 diabetes, hypertension or obstructive sleep apnoea.
These conditions may require medical treatment.
However, the presence of a weight-related health problem does not automatically outweigh the risks of appetite-suppressing medication in someone with an active eating disorder.
Both conditions need appropriate assessment.
In some cases, clinicians may recommend prioritising eating disorder treatment before pursuing intentional weight loss.
In others, management of an associated medical condition may need to occur alongside psychological treatment.
The appropriate approach depends on individual circumstances.
Professional support can be particularly important when someone is managing an eating disorder alongside another medical condition.
This may include an eating disorder specialist, GP, weight-management clinician, psychologist or dietitian.
With your consent, communication between professionals can help ensure that treatment decisions reflect both physical and psychological needs.
Personal support from trusted friends or family members may also be helpful.
However, lacking a strong personal support network should not automatically exclude someone from healthcare.
The aim is to identify what support is needed and how it can be provided.
There are situations where appetite-suppressing medication may create additional risks for someone experiencing disordered eating.
These require careful assessment rather than blanket assumptions.
If you regularly restrict food intake, appetite suppression may make adequate nutrition more difficult.
This could worsen an existing pattern of restriction and binge eating.
For some people, reduced hunger may also make it harder to recognise when they’re eating too little.
Potential consequences include nutritional inadequacy, dehydration and worsening eating disorder behaviours.
Active restrictive eating should therefore be discussed with an appropriately qualified healthcare professional before GLP-1 treatment is considered.
It would be inaccurate to claim that GLP-1 medicines inevitably cause someone with binge eating disorder to develop anorexia nervosa.
However, the possibility of worsening restrictive behaviours is an important clinical concern.
A history of anorexia nervosa or bulimia nervosa requires careful consideration when assessing suitability for weight loss medication.
Appetite suppression and intentional weight loss may be problematic for someone vulnerable to restrictive eating, purging or other eating disorder behaviours.
However, a past eating disorder diagnosis is not automatically a formal contraindication to every GLP-1 medicine.
The relevant product information and individual clinical circumstances must be considered.
Specialist assessment may be appropriate, particularly where symptoms remain active or relapse risk is significant.
Trauma can contribute to eating difficulties for some people, but not everyone with binge eating disorder has experienced trauma.
Where trauma-related symptoms are present, they may need appropriate psychological support.
However, it would be inaccurate to suggest that weight loss medication will necessarily remove someone’s coping mechanism and cause a psychological crisis.
There is insufficient evidence to make that prediction.
The important consideration is whether current mental health symptoms, eating patterns and available support make treatment appropriate.
Psychological care should address the person’s individual needs rather than assuming a particular cause of their eating disorder.
If you have active binge eating disorder, an appropriate assessment is important before starting appetite-suppressing medication.
A clinician should understand your eating patterns, medical history and any symptoms suggesting restriction, purging or other eating disorder behaviours.
Where an eating disorder is suspected, NICE recommends referral for specialist assessment.
A weight-management provider should recognise when specialist input is required and avoid treating an eating disorder solely through weight loss medication.
If you feel your eating disorder concerns are being overlooked, you can ask for further assessment or a referral.
GLP-1 medicines should not be presented as a cure for binge eating disorder.
Even if someone experiences reduced appetite or fewer binge episodes during treatment, this does not establish that the underlying eating disorder has resolved.
Recovery may involve changes in eating patterns, body image, emotional coping and psychological wellbeing.
Treatment should focus on these broader outcomes rather than assuming that appetite suppression is sufficient.
If weight-management medication is being considered for someone with binge eating disorder, the assessment and support arrangements are particularly important.
An initial assessment should consider the person’s eating disorder symptoms and overall health.
This may include the frequency and nature of binge episodes, restrictive eating, compensatory behaviours, previous treatment, current mental health and relevant medical conditions.
Clinicians should also consider whether the person meets the prescribing criteria for weight-management medication.
An eating disorder diagnosis should not be used as the sole basis for prescribing GLP-1 treatment.
Where appropriate, an eating disorder specialist should contribute to decisions about treatment timing and monitoring.
At Bodyline, we offer specialised support for patients with mental health considerations, including assessment of relevant mental health and eating concerns.
Where specialist eating disorder input is needed, this should form part of the decision about whether treatment is appropriate.
Psychological treatment is central to binge eating disorder care.
The NICE guideline on eating disorders recommends guided self-help focused on binge eating disorder, followed by CBT-ED where appropriate.
CBT-ED can help people recognise triggers, establish regular eating patterns, address body image concerns and develop strategies to reduce binge eating.
Other psychological approaches may be considered by specialist services depending on individual needs.
However, it would be inaccurate to claim that combining GLP-1 medication with therapy has been proven more effective than psychological treatment alone for binge eating disorder.
That question requires further research.
If weight-management medication is prescribed for a separate licensed indication, psychological treatment for binge eating disorder should continue as clinically appropriate.
Monitoring should reflect the individual’s eating disorder symptoms, physical health and prescribed medication.
This may include reviewing food intake, binge eating frequency, restrictive behaviours, mood and medication side effects.
Changes in weight should be interpreted carefully, particularly where weight-focused monitoring could increase eating disorder distress.
There is no universal NICE or MHRA requirement for weekly or fortnightly appointments for everyone with binge eating disorder receiving GLP-1 treatment.
The monitoring schedule should be agreed according to clinical need.
New or worsening restriction, purging, significant nutritional difficulties or mental health symptoms require prompt assessment.
Thoughts of self-harm or suicide should always be taken seriously and require appropriate urgent support.
A dietitian with experience in eating disorders may help someone develop regular, nutritionally adequate eating patterns.
This is particularly important where reduced appetite makes it difficult to eat enough.
However, eating disorder treatment should not focus on rigid calorie restriction or weight-loss targets.
NICE advises people receiving CBT-ED for binge eating disorder not to attempt weight loss through dieting during treatment because this may trigger further binge eating.
Nutritional advice should support recovery and be coordinated with psychological care.
If GLP-1 treatment is prescribed for an appropriate indication, understanding possible effects on appetite and eating patterns is important.
GLP-1 medicines are generally started at lower doses and increased according to their licensed dosing schedules.
Some people experience reduced appetite early in treatment, although the timing and intensity vary.
For someone with binge eating disorder, changes in hunger and fullness may require additional attention.
A reduction in appetite should not be treated as permission to skip meals or restrict food excessively.
Regular eating is an important component of binge eating disorder treatment.
Nausea, vomiting and other gastrointestinal symptoms can also affect food intake.
If these symptoms are persistent or severe, contact your prescriber rather than independently changing your medication dose.
Monitoring binge eating behaviours can help you and your treatment team understand whether symptoms are changing.
This may involve recording the frequency of episodes, associated emotions, triggers and feelings of loss of control.
However, detailed tracking of food quantities or calories may be distressing or counterproductive for some people.
Your therapist or eating disorder specialist can help determine an appropriate monitoring approach.
A reduction in the amount eaten during an episode does not necessarily mean that binge eating disorder is improving.
Loss of control, distress and other psychological symptoms remain important.
If symptoms worsen or new restrictive or compensatory behaviours emerge, seek clinical advice.
Some people experience changes in their relationship with food when appetite decreases.
These changes may feel positive, uncomfortable or emotionally complicated.
However, there is insufficient evidence to conclude that GLP-1 treatment routinely causes a temporary period of emotional vulnerability or that such symptoms will reliably settle after a few weeks.
New or worsening anxiety, depression or significant changes in behaviour should be assessed rather than dismissed as a normal adjustment.
If eating has been associated with emotional coping, psychological support may help develop additional strategies.
GLP-1 medicines can cause nausea, vomiting, diarrhoea, constipation and other gastrointestinal symptoms.
These effects may complicate eating disorder management, particularly if they interfere with regular meals or adequate hydration.
Persistent vomiting or diarrhoea can lead to dehydration.
Severe, persistent abdominal pain, especially if it radiates to the back, requires urgent medical assessment because it may indicate acute pancreatitis.
These symptoms should not be assumed to be ordinary treatment effects.
Your healthcare team should consider both medication side effects and eating disorder symptoms when reviewing changes in food intake or behaviour.
Binge eating disorder can require ongoing treatment and support, although many people recover with appropriate care.
Long-term weight-management decisions should be considered separately from eating disorder recovery.
GLP-1-based weight-management medicines may be prescribed for ongoing treatment, depending on their licensed indication, clinical response and individual circumstances.
However, there is insufficient evidence to establish how long someone with binge eating disorder would need GLP-1 treatment to control binge episodes.
These medicines are not licensed for that purpose.
Some people regain weight after stopping GLP-1 treatment, but this does not establish that binge eating symptoms will necessarily return.
The decision to continue or stop medication should be based on its prescribed indication, benefits, tolerability and clinical guidance.
Our guide on how long to stay on weight loss injections explores these considerations in detail.
Recovery from binge eating disorder involves more than changes in body weight or appetite.
It may include reducing binge eating episodes, establishing regular eating patterns, improving body image and developing effective ways of managing distress.
Psychological treatment can help address these areas.
Importantly, recovery does not depend on achieving a particular weight.
NICE emphasises that weight loss is not a therapy target in itself when treating binge eating disorder.
If weight management is also medically indicated, it should be considered in a way that does not undermine eating disorder treatment.
If you stop GLP-1 weight-management treatment, your prescriber can advise on what to expect.
There is no universal requirement to taper Wegovy or Mounjaro gradually to prevent withdrawal or weight regain.
Do not change the dose or stop prescribed treatment without discussing your circumstances with the responsible clinician, particularly if the medicine is also being used for diabetes.
Appetite may increase after treatment stops, and some people regain weight.
However, the effect on binge eating symptoms is not well established.
If you have an eating disorder history, it may be helpful to plan appropriate psychological support and monitor for changes in eating patterns.
When you have binge eating disorder, progress should be measured by more than weight loss.
Important outcomes may include fewer binge episodes, reduced distress, more regular eating patterns, improved body image and better quality of life.
Feeling less controlled by eating disorder behaviours is a meaningful achievement, regardless of changes in weight.
Physical health improvements may also matter, but they should not overshadow recovery from the eating disorder itself.
Deciding whether to consider weight loss medication when you have binge eating disorder requires careful discussion with qualified healthcare professionals.
The decision depends on your medical circumstances, current eating disorder symptoms and whether you meet the criteria for a licensed treatment.
Are you currently experiencing binge eating episodes, restrictive eating or other eating disorder symptoms?
Have you received an assessment from an eating disorder specialist?
Are you receiving guided self-help or psychological therapy?
Do you have a medical condition for which GLP-1 treatment is licensed and clinically appropriate?
Could appetite suppression interfere with your nutritional intake or eating disorder recovery?
What monitoring and support would be available if treatment were considered?
These questions can help you and your healthcare team decide which concerns need addressing first.
Be open with your healthcare provider about your eating disorder history and current symptoms.
This includes binge eating, restriction, purging, compulsive exercise or other behaviours that may affect treatment safety.
Your clinician should explain the evidence, limitations and potential risks of GLP-1 medication in your circumstances.
They should also explain whether specialist eating disorder assessment is needed.
If you’re unsure about a recommendation, ask for clarification or a second opinion.
If you’re over 70 and considering weight loss treatment alongside binge eating concerns, our specialised support for older adults discusses age-related considerations, including nutritional health and appropriate clinical monitoring.
For patients with complex medical histories or multiple health conditions alongside eating concerns, our personalised clinical weight loss care provides information about individualised weight-management assessment.
However, specialist weight-management services do not replace dedicated eating disorder treatment where this is needed.
If binge eating disorder is suspected, your GP can arrange appropriate assessment and referral.
The NHS guide to binge eating disorder treatment explains the recommended approaches, including guided self-help and CBT.
Binge eating disorder can be distressing and difficult to discuss, particularly when someone is also experiencing weight-related stigma.
However, effective treatments are available, and recovery is possible.
GLP-1 medicines such as Wegovy and Mounjaro are being investigated for their potential effects on binge eating behaviours, but the evidence remains preliminary.
They are not currently licensed in the UK to treat binge eating disorder and should not be presented as established alternatives to psychological treatment.
For some people with binge eating disorder, separate medical weight-management treatment may be appropriate after careful assessment.
For others, appetite suppression could complicate eating disorder recovery, making specialist input particularly important.
The priority is ensuring that treatment addresses your physical and psychological needs without encouraging harmful eating patterns.
Recovery from binge eating disorder is not defined by a number on the scale.
It involves improving your relationship with food, reducing distress and developing sustainable patterns of eating and coping.
If you’re considering weight loss medication and have concerns about binge eating, speak with your GP or an appropriately qualified healthcare professional.
They can assess your individual circumstances, discuss the available evidence and help you access specialist eating disorder support where needed.
Book a consultation today to discuss whether medical weight management may be appropriate for your circumstances.
At Bodyline Clinic, our team considers relevant medical history and mental health concerns when assessing treatment suitability.
Where an eating disorder is suspected or specialist support is required, appropriate assessment and coordinated care should take priority.
Your physical health matters, but so does your recovery from binge eating disorder.
BMI calculator
Enter your height and weight to work out your Body Mass Index in seconds.
Your BMI
Find out where you sit and what your options are
Your BMI
Our CQC-regulated clinical team will confirm your eligibility at consultation, in clinic or by video.
CQC regulated 4.8 on Trustpilot
If you'd like advice on your health and wellbeing, our team can talk you through the services we offer.
Explore our servicesWe'd recommend speaking to your GP, who can check everything is OK and offer the right support.
BMI ranges work differently for under 18s. Please speak to your GP for advice.
Please check your height and weight.
Contact us today
Find out more about how we can treat and support you to improve your health and wellbeing.
No-obligation advice from our CQC-regulated team, in clinic or by video.
